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ABSTRACT 
Objective: The objective of this research compares effectiveness and safety of high-dose oral ibuprofen and standard dose for treatment 
symptomatic PDA. 
Methods: A retrospective cohort study was carried out in 126 preterm infants with patent ductus arteriosus (PDA) who received oral ibuprofen and 
hospitalized in neonatal intensive care unit and sick newborn ward during January 2010-December 2014, preterm infants with PDA was assigned to 
high dose (10-10-10 mg/kg/day) oral ibuprofen group and standard dose group (10-5-5 mg/kg/day), 63 patients within in each group. 
Results: Baseline characteristics were no significant difference between two groups. The closure rate of the ductus arteriosus of the high dose group 
was significantly higher (82.5%) than in standard dose group (66.7%) (p=0.04). So, lower rate of re-open and PDA ligation. However, ductus arteriosus 
closure rate at discharge was not significantly different. There was no significant difference between two groups in adverse drug reaction. 
Conclusion: The results obtained for this study show the high dose of oral ibuprofen is more effectiveness than the standard dose for closing PDA in 
preterm infants without increasing the adverse drug reaction rate. 
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INTRODUCTION 
Patent Ductus Arteriosus (PDA) is the most common cardiovascular 
abnormality in preterm neonates with the reported incidence as 
high as 77% in Texas [1-2] and 26.9% in newborns aged less than 33 
w gestation in Thailand [3]. Neonates with PDA have higher 
respiratory failure rates, lower survival rates, and increased risk of 
intracranial hemorrhage (IVH), bronchopulmonary dysplasia (BPD), 
and necrotizing enterocolitis (NEC)[3-5]. 
Ibuprofen is a nonselective non steroidal anti-inflammatory drug that 
induces the closure of the PDA by inhibiting cyclo-oxygenase. Now 
PDA can be treated with oral ibuprofen (10-5-5 mg/kg/day). However 
many studies [6-12] found the higher failure rate in this dose and 
suggest that the failure of pharmacologic treatment for PDA closure 
might be due to inadequacy of 10-5-5 mg/kg/day. Moreover, Desfrere 
et al. [10] and Hirt et al. [11] show that the closure rate of PDA was 
related to the cumulative dose of ibuprofen administrated. In addition, 
Dani et al. [12] found high-dose ibuprofen (20-10-10 mg/kg/day) is 
more effective than the standard dose (10-5-5 mg/kg/day) without 
increasing the adverse effect rate [12]. 
In case of Chiangrai Prachanukroh hospital, the present has two 
regimens of oral ibuprofen for PDA management, 10-5-5 mg/kg/day 
and 10-10-10 mg/kg/day that follow Varaporn S [13] whom 
demonstrated the recommended dose regimen of oral ibuprofen is 
10-10-10 mg/kg/day in Thai neonates whom with gestational age 
less than 32 w. This present found ibuprofen suspension could 
reduce the symptomatic PDA without any significant side effects. 
The author preformed a retrospective cohort study to compare efficacy 
and safety of high dose and standard dose oral ibuprofen for closure of 
PDA in preterm infants which would be help pediatrician to be 
appropriate determine the dose of oral ibuprofen for PDA treatment. 
METERIALS AND METHODS  
The present study was a retrospective cohort study that approved 
by the internal ethical committee of research in human subject 
Chiangrai Prachanukroh Hospital, on 24 March 2015 and reference 
number is CR 0032.102/9212. 
All preterm infants which hospitalized in newborn critical care unit 
and sick newborn ward during January 2010 to December 2014 
were recruited in the present study. The criteria for enrollment were 
gestational age less than 37 w, clinical and/or echocardiography 
evidence of PDA by neonatologist and received three doses of oral 
ibuprofen either according to the standard regimen (an initial dose 
of 10 mg/kg, followed by two doses of five mg/kg each, after 24 and 
48 h) or per a high-dose regimen (an initial dose of 10 mg/kg and 
after 24 and 48 h) via an orogastric tube. 
The exclusion criteria were major congenital anomalies; persistent 
pulmonary hypertension, diagnosed by clinical and/or 
echocardiography when the presence of a right-to-left shunt and 
incomplete patient’s data. 
Clinical data and demographic information were collected by 
reviewing medical records of the enrolled patients.  
Statistical analysis 
The authors calculated that a sample size of at least 63 infants in 
each group was necessary for a power of 0.80 and p-value of 0.05. 
The baseline characteristics of the two groups were described in 
terms of mean values and SD, median value and range, or rate and 
percentage. The independent sample t-test, Mann-Whitney U test 
and Chi-square test or Fisher’s exact test was used to compare 
continuous normally distributed data, nonparametric continuous 
data, and categorical data, respectively. 
Multiple binary logistic regressions was performed to assess the 
predictive factors as the closure rate of PDA after the first oral 
ibuprofen course, the factors the authors analyzed were: the average 
postnatal age at first time of oral ibuprofen, received amikacin and 
meropenem during used oral ibuprofen and history of prenatal 
steroid, and assignment to the standard or high-dose oral ibuprofen 
regimen group. Effect estimates are expressed as adjusted odd ratio. 
RESULTS 
Subject demographic and baseline characteristics 
A retrospective cohort study was carried out in 126 preterm 
infants with patent ductus arteriosus (PDA) who received oral 
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ibuprofen and hospitalized in neonatal intensive care unit and sick 
newborn ward during January 2010-December 2014. The author 
divided preterm infants into two groups to receive either the 
standard dose regimen (10-5-5 mg/kg/day; n=63) or the high-
dose regimen (10-10-10 mg/kg/day; n=63). There were no 
significant differences in baseline characteristics, including 
gestational age, birth weight, gender, delivery method, APGAR 
scores, fluid intake at day of life 1-7 and on first day received oral 
ibuprofen. However, there was significant higher average 
postnatal age at first day of oral ibuprofen in the high-dose group 
than in standard dose group (p=0.00), history of prenatal steroid 
in standard dose group (49.2%) is higher than in high-dose group 
(30.2%) (p=0.03) and lower number of preterm infants in the 
standard dose group received amikacin and meropenem during 
used oral ibuprofen than in high-dose group (p=0.02). The 
baseline characteristic data were shown in table 1. 
 
Table 1: Baseline characteristics of infants in the standard dose and high dose groups of oral ibuprofen in preterm infants with PDA 
Baseline characteristics Standard dose group (n=63) High dose group (n=63) p-valued 
Gestational age (week)a 30.6±2.9 30.4±2.7 0.81 




53 (84.1) 48 (76.2) 0.26 
Vacuum extractor 1 (1.6) 0 (0) 1
Cesarean section 9 (14.3) 15 (23.8) 0.17 
SexPa 
Male 36 (57.1) 33 (52.4) 0.59 
Female 27 (42.9) 30 (47.6) 0.59 
APGAR score (score)Pb 
0 min 6.5±2.1 6.6±2.4 0.81 
5 min 7.7±1.2 7.6±2.0 0.71 
10 min 8.1±1.1 8.0±1.9 0.87 
ComorbidityPa 
Respiratory distress 59 (93.7) 56 (88.9) 0.34 
Birth asphyxia 0 (0) 5 (7.9) 0.05 
Pneumonia 2 (3.2) 1 (1.6) 1.00 
Sepsis 2 (3.2) 1 (1.6) 1.00 
Fluid intake (ml/kg/day)Pb   
DOL 1 69.1±13.8 69.2±10.1 0.96 
DOL 2 70.8±14.7 71.1±11.7 0.88 
DOL 3 85.5±17.7 83.4±14.9 0.74 
DOL 4 98.1±21.6 97.0±17.1 0.76 
DOL 5 114.2±20.2 110.6±17.4 0.29 
DOL 6 125.5±20.4 122.6±19.6 0.41 
DOL 7 135.3±19.3 129.2±20.3 0.09 
Co-medicationPa    
 Ampicillin+gentamicin 25 (39.7) 15 (23.8) 0.05 
 Ampicillin+cefotaxime 18 (28.6) 12 (19.0) 0.21 
 Ceftazidime+amikacin 8 (12.7) 14 (22.2) 0.16 
 Meropenem+amikacin 7 (11.1) 17 (27.0) 0.02 
 Dexamethasone 4 (6.3) 1 (1.6) 0.36Pe 
 OthersPc 21 (45.7) 25 (54.3) 0.46Pe 
Diagnosis of PDAPa    
 Clinical  39 (61.9) 28 (44.4) 0.05 
 Echocardiography 0 0 N/A 
 Clinical and echoPf 24 (38.1) 35 (55.6) 0.05 
Hospital stay (day)Pb 50.9±26.6 51.62±29.9 0.90 
P
a
Pmean±SD, Pb P rate (%), PcP others: vancomycin and/or cefoperazone and sulbactam and/or piperacillin and tazobactam and/or furosemide, PdP Chi-
square test, PeP Fisher’s exact test, Pf P echocardiography and DOL: day of life. 
 
Day of life 
Multiple logistic regression analysis used to demonstrate the 
relation between those factor and PDA closure rate. The author 
found that prenatal steroid (adjusted OR ratio 1.5; 95% CI: 0.6-3.5), 
co-medication during on oral ibuprofen: meropenem and amikacin 
(adjusted OR 0.6; 95% CI: 0.2-2.0) and postnatal age at first day 
received oral ibuprofen (adjusted OR 1.0; 95% CI: 1.0-1.0) were not 
related with the PDA closure rate (table 2).  
Efficacy 
After the first course of oral ibuprofen, the PDA closed in 42 (66.7%) 
of the patients assigned to the standard dose oral ibuprofen group 
versus 52 (82.5%) of those enrolled in the high dose oral ibuprofen 
group (p=0.04). The reopening of ductus arteriosus after first course 
was 16 (25.4%) of standard dose and 8 (12.7%) (p=0.07) of the 
high-dose group.  
The second course started when failure to closure DA after complete 
the first course which was closed in five and eight patients of the 
standard and high group, respectively. Surgical closure of PDA was 
needed in four patients in standard dose group and in one patient in 
the high-dose group. At the time of discharge, 57 patients in 
standard dose group and 54 patients in high dose group were with 
PDA (table 3). 
 
Table 2: Baseline characteristic and PDA closure rate 
Baseline characteristic Adjusted OR (95% Cl) p-value 
Prenatal steroids 1.5 (0.6–3.5) 0.30 
Comedication: meropenem 
and amikacin 
0.6 (0.2-2.0) 0.48 
Postnatal age at 1PstP oral 
ibuprofen 
1.0 (1.0-1.0) 0.07 
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Table 3: Efficacy of treatment for the standard dose and high dose groups of oral ibuprofen in preterm infants with PDA 
e 
 Standard dose group (n=63) High dose group (n=63) p-valuea 
 Rate (%)  
PDA occurrence First course of oral ibuprofen  
Closure 42 (66.7) 52 (82.5) 0.04 
Patent 21 (33.3) 11 (17.5) 
Reopen 16 (25.4) 8 (12.7) 0.07 
 Second course of oral ibuprofen  
Closure 5 (55.6) 8 (53.3) 0.32Pb 
Patent 4 (44.4) 7 (46.7) 
Surgical closure 4 (6.3) 1 (1.6) 0.42Pb 
PDA at discharge 57 (90.4) 54 (85.7) 0.58Pb 
P
a
P Chi square test,Pb P Fisher’s exact 
 
Table 4: Adverse drug reactions in standard dose and high dose groups of oral ibuprofen in preterm infants with PDA 
Adverse drug reactions Standard dose group (n=63) High dose group (n=63) 
Renal function   
Acute kidney injury (rate)Pa 2 (3.1) 1 (1.5) 
 Serum creatinine (mg/dl)Pb   
 Before 3 doses oral ibuprofen 0.6±0.3 0.7±0.3 
 After 3 doses oral ibuprofen 0.6±0.5 0.6±0.4 
Oliguria (rate)Pa 0 1 (1.5) 
 Urine output (ml/kg/h)Pb   
1PstP day on ibuprofen (Day1) 3.6±1.6 3.8±1.6 
2PndP day on ibuprofen (Day 2) 3.7±1.8 3.6±1.6 
3PrdP day on ibuprofen (Day 3) 4.0±1.5 3.5±1.5 
1PstP day after ibuprofen (Day 4) 4.4±1.8 3.9±1.9 
2PndP day after ibuprofen (Day 5) 4.4±2.2 4.0±1.7 
3PrdPday after ibuprofen (Day 6) 4.3±2.1 3.9±1.9 
4PthP day after ibuprofen (Day 7) 4.4±2.2 3.7±1.8 
Bleeding disorder (rate)Pa 6 (9.5) 6 (9.5) 
 Respiratory tract 6 (9.5) 6 (9.5) 
 Upper GI bleeding 0 0 
Thombocytopenia 0 0 
Platelets (cell/mm3)Pb   
 Before 3 doses oral ibuprofen  208 682±8289  247 000±16 242 
 After 3 doses oral ibuprofen  308 714±19 273  306 873±19 277 
Necrotizing enterocolitis 0 0 
Dead (rate)Pa 4 (57.1) 3 (42.9) 
P
a
Pmean±SD, PbP rate (%), 
 
Safety 
Adverse drug reaction was similar in standard dose group and high-
dose group 8 (12.7%) versus 8 (12.7%). Bleeding disorder in 
respiratory tract was the most adverse drug reaction in this present 
but similar between two groups. Renal function, the change of serum 
creatinine increased 2-fold from baseline found in the standard dose 
group more than high-dose group 2 (3.1%) versus 1 (1.5%) and only 
one patient in the high-dose group developed oliguria. None of 
patients had necrotizing enterocolitis. (table 4). 
DISCUSSION 
The optimal dose of oral ibuprofen for closing PDA is unclear; this 
present was the first retrospective cohort study attempting to 
compare the effectiveness and safety between high dose and 
standard dose of oral ibuprofen in Chiangrai Prachanukroh Hospital, 
that did not have the standard treatment for PDA in preterm infants. 
Both oral ibuprofen regimen in this present are used in real practice 
due to standard dose is recommended in many suggestion [8-14] 
and high doses is recommended in Varaporn et al. [13], studied in 
Queen Sirikit National Institute of Child Health Ministry of Public 
Health, Thailand. 
Many clinical parameters associated with ductus arteriosus closure 
in preterm infants either birth weight, gestational age, delivery 
method, APGAR score, total fluid at the first week of life, co-
morbidity, prenatal steroid or postnatal age at the first day of 
received oral ibuprofen [2, 14-15]. In the present study, they were 
not significant difference between two groups, except prenatal 
steroids, received amikacin and meropenem and postnatal age at the 
first day of received oral ibuprofen. Prenatal steroids were also 
reported to decrease the nitric oxide productivity, vasodilator, 
sensitivity of a ductus arteriosus to prostaglandin and increase 
vascular contracted through a high calcium influx on smooth muscle 
leading to higher PDA closure rate [2]. However, infants in this 
present started oral ibuprofen at day of life 10, that take long time to 
infants to have steroids effect from maternal, thus prenatal steroids 
higher rate in the standard dose group may not relate PDA closure 
rate. The next difference factor was postnatal age, Hirt et al. [11] 
found important effect of postnatal age on ibuprofen. Ibuprofen 
clearance increase in the older age of neonate due to the maturity of 
renal development; which would increase the clearance of ibuprofen 
from the body resulting in lowering ibuprofen in blood. The lower 
level of ibuprofen in the blood stream could not enough to close 
PDA. These reasons explain that the older subjects were less 
successful on the DA closure rate by oral ibuprofen. Nevertheless, 
this present found higher postnatal age and higher closure rate in 
high dose group. The explanation was the high dose group even 
though higher rate clearance but an ibuprofen blood level is also 
high enough for closing PDA together with anatomical closure. The 
last factor that significant difference between two groups was the 
use of amikacin and meropenem during received oral ibuprofen. 
Reese et al. [16] studied vasodilator properties from medication that 
used in neonate and found that gentamicin and aminoglycoside had 
vasodilator properties because this medicine inhibit phospholiphase 
C and decrease calcium ion due to vascular dilate. On the other hand, 
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Reese et al. [16] studied in very high dose of gentamicin and 
aminoglycoside, 100-1000 fold in real practice; therefore this factor 
could not affect to PDA closure rate. Nevertheless when the multiple 
binary logistic regression was tested, all above difference factors 
were not significant related to PDA closure rate. 
The effectiveness of this present is conform to the study of Desfrere 
et al. [10] whom found that high dose (15-7.5-7.5 mg/kg/day), 
higher PDA closure rate. Furthermore, Dani et al. [12], the latest 
study compare first course of high dose (20-10-10 mg/kg/day) and 
standard dose (10-5-5 mg/kg/day), found the high-dose ibuprofen 
regimen was more effective than the standard dose regimen in 
closing PDA in preterm infants<29 w of gestational without 
increasing adverse drug reaction rate. Moreover, this present found 
the reopen rate and PDA ligation rate in high-dose group were 
twofold and fourfold, respectively, lower than the standard dose. 
These shown the benefit of oral ibuprofen high dose. However, time 
duration from the first course to the second course was not 
specified, which might interfere the closing effect from anatomical 
closure. In other studies, closure rate in second course, PDA at 
discharge and long of hospital stay were not significant difference 
between two groups. The difference from other studies may be 
owing to, first, the increasing of postnatal age which resulting to the 
higher rate of anatomical closing PDA. Second, the final outcome 
(closing PDA) was evaluate using only clinical sign for diagnosis that 
can differ from physician to physician, which would affect to the 
closure rate. Third, the hospital policy of infant’s bodyweight at 
discharge having a body weight at least 2000 grams and the chronic 
lung disease from the long use of oxygen resulting in older age of a 
patient at discharge. Thus, longer hospital stay, higher postnatal age 
at discharge, higher rate of PDA closure. Diagnoses by clinical sign 
were used more in the standard dose group than in the high-dose 
group, which may be because of in a diagnosis process by clinical 
sign with the wide PDA size is easy to detect. Thus, in the standard 
dose group, with younger postnatal age, wide PDA size usually found 
an obviously less and difficult to close by nature. However, they are 
significant between two groups. 
Ibuprofen is non-steroid anti-inflammatory drugs (NSAIDs) [17] 
effects to several body organs especially gastrointestinal (GI), 
inhibition cyclo-oxygenase can decrease mucus secretion and thus, 
induced gastric ulcer and inhibition of thromboxane A2 production 
relates to gastric bleeding. In addition, the decreasing of PGI2 and 
PGE2, vasodilator at renal, controlling blood circulation inside of renal; 
effect to interstitial inflammatory and increase serum creatinine level. 
But safety details not a difference between two groups accordingly 
with Dani et al.[12], Desfrere et al. [10] and Hirt et al. [11]. 
The present study has several limitations. The major limitation is its 
retrospective design may be vulnerable to confounding errors and 
bias. Second, this study lacks some echocardiography data due to 
PDA size when diagnosis of PDA and PDA closure at a complete 
course of oral ibuprofen. Future study should be a prospective 
randomized study based on echocardiography and clinical data, 
study in all types of oral ibuprofen regimens in Chiangrai 
Prachanukroh hospital and should study in infants of gestational age 
between 28-32 w, aim to decrease confounding variable related to 
PDA closure from less or more gestational age. 
CONCLUSION 
In summary, the present data indicate that high dose of oral 
ibuprofen (10-10-10 mg/kg/day) is more effectiveness than the 
standard dose (10-5-5 mg/kg/day) for treatment of PDA in preterm 
infants without increasing adverse drug reactions. 
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